Innate Pharma S.A. (IPHYF)

Market Cap	118.78M -30.7%
Revenue (ttm)	10.57M -55.2%
Net Income	-57.74M
EPS	-0.65
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	1,902
Open	1.373
Previous Close	n/a
Day's Range	1.373 - 1.373
52-Week Range	1.310 - 2.155
Beta	0.54
RSI	42.75
Earnings Date	Mar 26, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 174
• Stock Exchange: OTCMKTS
• Ticker Symbol: IPHYF

Financial Performance

In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.

Financial numbers in EUR